Paul Sweetnam - 08 Oct 2026 Form 3 Insider Report for Retension Pharmaceuticals, Inc.

Reporting relationship
Chief Scientific Officer
Issuer ticker
N/A
Reported as of
08 Oct 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
08 Oct 2026, 18:37:48 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Alex Schwartz, Attorney-in-Fact

Key filing fact

Paul Sweetnam filed Form 3 for Retension Pharmaceuticals, Inc. on 08 Oct 2026.

Key facts

  • This page summarizes Paul Sweetnam's Form 3 filing for Retension Pharmaceuticals, Inc..
  • 0 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 08 Oct 2026, 18:37.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002156367 Primary reporting owner

Sweetnam Paul

Relationship
Chief Scientific Officer
Address
1104 WEST BROAD STREET, SUITE 1029, FALLS CHURCH
Signature
/s/ Alex Schwartz, Attorney-in-Fact
Signature date
08 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
402,577
Date
08 Oct 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
08 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
80,516
Exercise price
$1.43
Footnotes
F1
No ticker holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
08 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
128,825
Exercise price
$2.43
Footnotes
F2
No ticker holding Derivative

Series A Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
08 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,026
Exercise price
Footnotes
F3
No ticker holding Derivative

Series B Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
08 Oct 2026
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
2,640
Exercise price
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Granted to the Reporting Person on September 23, 2024. The stock options vest in 1/36 monthly increments, with the first vesting date on December 21, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F2

Granted to the Reporting Person on October 31, 2025. The stock options vest in 1/36 monthly increments, with the first vesting date on September 29, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F3

The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series A Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.

Footnote F4

The Series B Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series B Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series B Preferred Stock has no expiration date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .